DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A

DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A

Introduction Emicizumab effectively prevents bleeding in people with haemophilia A (PwHA), but is a burden for national healthcare budgets and consequently may limit access. According to the drug label, dosing of emicizumab is based on body weight with fixed intervals of 7, 14 or 28 days, which lead...

Full description

Bibliographic Details
Main Authors: Marjon H Cnossen, Karin Fijnvandraat, Ron Mathot, Antoine C G Egberts, Rolf T Urbanus, Anouk Donners, Konrad van der Zwet, Ilmar Kruis, Roger Schutgens, Kathelijn Fischer
Format: Article
Language:English
Published: BMJ Publishing Group 2023-06-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/13/6/e072363.full

Internet

https://bmjopen.bmj.com/content/13/6/e072363.full

Similar Items